N6-Isopentenyladenosine Hinders the Vasculogenic Mimicry in Human Glioblastoma Cells through Src-120 Catenin Pathway Modulation and RhoA Activity Inhibition

Background: Vasculogenic mimicry (VM) is a functional microcirculation pattern formed by aggressive tumor cells. Thus far, no effective drugs have been developed to target VM. Glioblastoma (GBM) is the most malignant form of brain cancer and is a highly vascularized tumor. Vasculogenic mimicry represents a means whereby GBM can escape anti-angiogenic therapies. Methods: Here, using an in vitro tube formation assay on Matrigel, we evaluated the ability of N6-isopentenyladenosine (iPA) to interfere with vasculogenic mimicry (VM). RhoA activity was assessed using a pull-down assay, while the modulation of the adherens junctions proteins was analyzed by Western blot analysis. Results: We found that iPA at sublethal doses inhibited the formation of capillary-like structures suppressing cell migration and invasion of U87MG, U343MG, and U251MG cells, of patient-derived human GBM cells and GBM stem cells. iPA reduces the vascular endothelial cadherin (VE-cadherin) expression levels in a dose-dependent manner, impairs the vasculogenic mimicry network by modulation of the Src/p120-catenin pathway and inhibition of RhoA-GTPase activity. Conclusions: Taken together, our results revealed iPA as a promising novel anti-VM drug in GBM clinical therapeutics.

[1]  M. Zhang,et al.  Long non‐coding RNA HULC stimulates the epithelial–mesenchymal transition process and vasculogenic mimicry in human glioblastoma , 2021, Cancer medicine.

[2]  S. Faure,et al.  Vasculogenic mimicry, a complex and devious process favoring tumorigenesis - Interest in making it a therapeutic target. , 2021, Pharmacology & therapeutics.

[3]  Wenyuan Zhao,et al.  Vasculogenic mimicry in carcinogenesis and clinical applications , 2020, Journal of Hematology & Oncology.

[4]  E. Crescenzi,et al.  N6-Isopentenyladenosine Enhances the Radiosensitivity of Glioblastoma Cells by Inhibiting the Homologous Recombination Repair Protein RAD51 Expression , 2020, Frontiers in Oncology.

[5]  Gao-lin Liu,et al.  Hypoxic induction of vasculogenic mimicry in hepatocellular carcinoma: role of HIF-1 α, RhoA/ROCK and Rac1/PAK signaling , 2020, BMC Cancer.

[6]  G. Fan,et al.  Molecular Mechanisms and Anticancer Therapeutic Strategies in Vasculogenic Mimicry , 2019, Journal of Cancer.

[7]  L. Peña,et al.  Vasculogenic mimicry-associated ultrastructural findings in human and canine inflammatory breast cancer cell lines , 2019, BMC Cancer.

[8]  L. Altucci,et al.  Histone Deacetylase Inhibitors Impair Vasculogenic Mimicry from Glioblastoma Cells , 2019, Cancers.

[9]  P. Remondelli,et al.  N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux , 2017, Cell Death and Differentiation.

[10]  S. Rubtsova,et al.  Cadherin-mediated cell-cell interactions in normal and cancer cells , 2017, Tissue barriers.

[11]  F. Oliver,et al.  Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin , 2017, Molecular Cancer.

[12]  K. Vijayan,et al.  Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA‐ROCK pathway , 2017, Cancer medicine.

[13]  M. Vitale,et al.  Antiglioma effects of N6‐isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor , 2017, International journal of cancer.

[14]  A. Ridley,et al.  Rho GTPases: Regulation and roles in cancer cell biology , 2016, Small GTPases.

[15]  R. Bianco,et al.  Src inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status , 2015, Oncotarget.

[16]  Jing Liu,et al.  Glioblastoma vasculogenic mimicry: signaling pathways progression and potential anti-angiogenesis targets , 2015, Biomarker Research.

[17]  R. Ronca,et al.  Antiangiogenic effects of N6‐isopentenyladenosine, an endogenous isoprenoid end product, mediated by AMPK activation , 2014, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  I. Verma,et al.  Mechanisms of neovascularization and resistance to anti-angiogenic therapies in glioblastoma multiforme , 2013, Journal of Molecular Medicine.

[19]  Mark A. Schroeder,et al.  Targeting Src Family Kinases Inhibits Bevacizumab-Induced Glioma Cell Invasion , 2013, PloS one.

[20]  J. Morgado-Díaz,et al.  Lysophosphatidic acid induces a migratory phenotype through a crosstalk between RhoA-Rock and Src-FAK signalling in colon cancer cells. , 2011, European journal of pharmacology.

[21]  Alfonso Martinez Arias,et al.  Faculty Opinions recommendation of Beta-catenin phosphorylated at serine 45 is spatially uncoupled from beta-catenin phosphorylated in the GSK3 domain: implications for signaling. , 2011 .

[22]  R. Nicholson,et al.  Src-mediated regulation of homotypic cell adhesion: implications for cancer progression and opportunities for therapeutic intervention. , 2011, Cancer treatment reviews.

[23]  L. Hodgson,et al.  Dynamics of the Rho-family small GTPases in actin regulation and motility , 2011, Cell adhesion & migration.

[24]  A. Malfitano,et al.  Involvement of Akt/NF‐κB pathway in N6‐isopentenyladenosine‐induced apoptosis in human breast cancer cells , 2010, Molecular carcinogenesis.

[25]  C. Gottardi,et al.  β-Catenin Phosphorylated at Serine 45 Is Spatially Uncoupled from β-Catenin Phosphorylated in the GSK3 Domain: Implications for Signaling , 2010, PloS one.

[26]  P. Mischel,et al.  A pilot study of everolimus and gefitinib in the treatment of recurrent glioblastoma (GBM) , 2009, Journal of Neuro-Oncology.

[27]  W. Nelson,et al.  Adherens and tight junctions: structure, function and connections to the actin cytoskeleton. , 2008, Biochimica et biophysica acta.

[28]  John Sampson,et al.  Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  W. Weis,et al.  Structure and mechanism of cadherins and catenins in cell-cell contacts. , 2007, Annual review of cell and developmental biology.

[30]  P. Villagrasa,et al.  Specific Phosphorylation of p120-Catenin Regulatory Domain Differently Modulates Its Binding to RhoA , 2006, Molecular and Cellular Biology.

[31]  G. Portella,et al.  N6‐isopentenyladenosine arrests tumor cell proliferation by inhibiting farnesyl diphosphate synthase and protein prenylation , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  I. Weissman,et al.  Incorporation of Bone Marrow-derived Flk-1-expressing CD34+ Cells in the Endothelium of Tumor Vessels in the Mouse Brain , 2004, Neurosurgery.

[33]  Haymo Kurz,et al.  Angiogenesis and vascular remodeling by intussusception: from form to function. , 2003, News in physiological sciences : an international journal of physiology produced jointly by the International Union of Physiological Sciences and the American Physiological Society.

[34]  A. Reynolds,et al.  Regulation of Rho GTPases by p120-catenin. , 2001, Current opinion in cell biology.

[35]  A. Reynolds,et al.  Identification of Src Phosphorylation Sites in the Catenin p120 ctn * , 2001, The Journal of Biological Chemistry.

[36]  K. Burridge,et al.  P120 Catenin Regulates the Actin Cytoskeleton via Rho Family Gtpases , 2000, The Journal of cell biology.

[37]  S. Narumiya,et al.  Pharmacological properties of Y-27632, a specific inhibitor of rho-associated kinases. , 2000, Molecular pharmacology.

[38]  P. Meltzer,et al.  Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. , 1999, The American journal of pathology.

[39]  G. Yancopoulos,et al.  Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF. , 1999, Science.

[40]  M. Wilm,et al.  The Enterotoxin from Clostridium difficile (ToxA) Monoglucosylates the Rho Proteins(*) , 1995, The Journal of Biological Chemistry.

[41]  C. Laezza,et al.  Recognition by natural killer cells of N6‐isopentenyladenosine‐treated human glioma cell lines , 2018, International journal of cancer.

[42]  P. Anastasiadis,et al.  p120 catenin: an essential regulator of cadherin stability, adhesion-induced signaling, and cancer progression. , 2013, Progress in molecular biology and translational science.

[43]  S. Étienne-Manneville.  Adherens junctions during cell migration. , 2012, Sub-cellular biochemistry.